Benzinga | Jun 17, 2021 09:11AM EDT

Danaher Scoops Up Aldevron In $9.6B Deal

* Danaher Corporation (NYSE:DHR) has agreed to acquire privately-held Aldevron for a cash purchase price of approximately $9.6 billion.

* Danaher expects to finance the acquisition using cash on hand or proceeds from the issuance of commercial paper.

* Founded in 1998, Aldevron manufactures plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications.

* It employs around 600 people.

* Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.

* Price Action: DHR shares closed at $244.74 on Wednesday.